Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Opdualag chalks up another failure, this time in the extension of an approved use.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
